Denosumab in Osteoporosis
Denosumab 60 mg subcutaneously every 6 months is indicated for postmenopausal women and men with osteoporosis at high risk for fracture, including those with glucocorticoid-induced osteoporosis, cancer treatment-induced bone loss, or those who have failed or are intolerant to bisphosphonates. 1, 2, 3
Indications
Primary Osteoporosis
- Postmenopausal women aged 60-90 years with BMD T-score ≤ -2.5 at lumbar spine or total hip 1
- Men with primary osteoporosis at high risk for fracture 4
- Patients with history of osteoporotic fracture 5, 3
- FRAX-adjusted 10-year risk for major osteoporotic fracture ≥10% or hip fracture >1% 3
Glucocorticoid-Induced Osteoporosis (GIOP)
- Adults ≥40 years at high or very high fracture risk on glucocorticoids ≥2.5 mg/day for >3 months 5
- When oral bisphosphonates are not appropriate due to comorbidities, patient preference, or adherence concerns 3
- Conditionally recommended over bisphosphonates in adults ≥40 years at high fracture risk 5
Cancer Treatment-Induced Bone Loss
- Postmenopausal women receiving aromatase inhibitors for breast cancer with T-score <-2.0 or ≥2 fracture risk factors 1, 2
- Men receiving androgen deprivation therapy for prostate cancer with similar risk criteria 1, 2
- Denosumab is the treatment of choice in these populations, reducing fractures by 50% in breast cancer patients and 62% in prostate cancer patients 1, 2
Dosing
Standard dose: 60 mg subcutaneously every 6 months 6
- No dose adjustment needed for renal impairment, including severe renal dysfunction (creatinine clearance <30 mL/min) 1, 7
- Median time to maximum concentration (Tmax) is 10 days 6
- Mean half-life of 25.4 days 6
- No accumulation with repeated dosing 6
Contraindications and Precautions
Absolute Contraindications
Critical Precautions
- Dental examination required before initiating therapy to assess for active oral infections or high-risk sites 1
- Avoid invasive dental procedures (extractions, implants) during treatment 1, 8
- Risk of osteonecrosis of the jaw (ONJ) is 0-1% with osteoporosis dosing, significantly lower than with oncologic dosing 1
Monitoring Requirements
Before Initiation
- Serum calcium and vitamin D levels 8
- Comprehensive dental examination 1, 8
- BMD measurement by DXA 5, 3
During Treatment
- Serum calcium monitoring regularly (hypocalcemia more pronounced with denosumab than bisphosphonates) 8
- Vitamin D levels evaluated intermittently 8
- No renal function monitoring required (unlike bisphosphonates) 8, 7
- BMD reassessment at 1-2 year intervals 2
Supplementation Requirements
Efficacy
Fracture Risk Reduction
- Vertebral fractures: 68% relative risk reduction (2.3% vs 7.2% with placebo) 1, 9
- Hip fractures: 40% relative risk reduction (0.7% vs 1.2% with placebo) 1, 9
- Nonvertebral fractures: 20% relative risk reduction (6.5% vs 8.0% with placebo) 1, 9
BMD Improvements
- Continuous BMD increases over 10 years of treatment 1, 10, 11
- Superior to alendronate at all skeletal sites (lumbar spine, femoral neck, total hip, distal radius) 12
- In men on ADT: 5.6% increase in lumbar spine BMD vs 1.0% loss with placebo 1
Duration of Treatment
Treatment duration should be up to 2 years initially for glucocorticoid-induced osteoporosis, with consideration for longer duration in primary osteoporosis based on ongoing fracture risk. 8
- Long-term data support efficacy and safety up to 10 years 1, 10, 13
- For cancer treatment-induced bone loss: continue for duration of endocrine treatment or up to 5 years 2
- Critical consideration: Denosumab has no residual effect beyond 6 months and requires sequential therapy upon discontinuation 14, 11
Critical Safety Concern: Rebound Effect Upon Discontinuation
Denosumab discontinuation is associated with a severe rebound effect including rapid bone loss and risk of multiple vertebral fractures approaching 20% in postmenopausal women. 15, 13, 11
Rebound Characteristics
- Bone turnover markers increase to 40-60% above pretreatment values within months 6, 15
- Loss of all BMD gains achieved during treatment 11
- Risk of multiple vertebral fractures particularly high 5, 15, 13
- Longer treatment duration associated with greater rebound effect 11
Management of Discontinuation
- Never stop denosumab abruptly 8, 15
- Transition to high-dose potent bisphosphonates to mitigate rebound 5, 11
- Sequential therapy with bisphosphonates recommended to maintain bone turnover markers in low range 5, 11
- Resume denosumab if new skeletal-related events occur after discontinuation 8
Adverse Effects
Common (Similar to Placebo)
- Arthralgia, nasopharyngitis, headache, extremity pain 1, 7
- No significant difference in overall adverse events or serious adverse events vs placebo 1
- Discontinuation due to adverse events: 2.4% vs 2.1% with placebo 1
Rare but Serious
- Osteonecrosis of the jaw: 0-1% with osteoporosis dosing (vs 0-0.5% with oral bisphosphonates) 1
- Atypical femoral fractures: rare, similar risk profile to bisphosphonates 1, 16
- Hypocalcemia: more pronounced than with bisphosphonates, especially in renal impairment 1, 8
- Increased risk of eczema and cellulitis 7
Clinical Positioning
Preferred Over Bisphosphonates When:
- Severe renal impairment (creatinine clearance <30 mL/min) 7, 14
- Intolerance to oral bisphosphonates 3, 4
- Poor adherence to oral therapy 7
- Cancer treatment-induced bone loss (first-line for breast cancer on AIs and prostate cancer on ADT) 1, 2
Second-Line After Bisphosphonates:
- In glucocorticoid-induced osteoporosis, use when bisphosphonates are not appropriate 5, 3
- In France, reimbursed as second-line after bisphosphonate trial 14
Advantages Over Bisphosphonates:
- No renal monitoring required 8, 7
- Superior BMD improvements at all skeletal sites 12
- Subcutaneous administration every 6 months improves adherence 7
- Can be used in severe renal impairment 7, 14